Exelixis, Inc.EXEL

Exelixis reported $610.8 million in revenue for the quarter ended 3 April 2026, with net income of $210.5 million and diluted earnings per share of $0.79, all filed in its latest 10-Q. The company’s operating income was $251.3 million and operating cash flow clocked in at $251.8 million, while its balance sheet showed $226.2 million in cash and $2.59 billion in assets against $657.8 million in liabilities. The numbers are solid, but they’re propped up by licence fees and collaboration services rather than blockbuster product sales.

Exelixis is a precision oncology outfit best known for CABOMETYX and COMETRIQ, two cancer drugs that got a 3% US wholesale price increase on 1 January 2026. The company’s cost of goods sold sits between 3.5% and 4.5% of net product revenues, a margin that hints at pricing power rather than manufacturing moats. Collaboration revenue-licence income and services-reached $55.8 million in Q1 2026, up from $42.2 million a year earlier, but still a single-digit slice of the top line.

The filing shows Exelixis spent $199.9 million on R&D in the quarter, nearly one-third of revenue, while property, plant, and equipment additions were a modest $1.5 million, indicating the company is still investing in its pipeline rather than bricks and mortar. Inventory rose by $3.4 million to $26.6 million, a line item that matters more for cash flow discipline than headline growth. Diluted weighted average shares outstanding were 267.3 million, and the company’s cash position gives it optionality, but the optics change when insiders sell shares between $49.73 and $50.61 on 3 June 2026 while the stock is priced at $50.

Exelixis trades on the Nasdaq and its financials are filed with the SEC. The company’s revenue is split between product sales and collaboration revenue, with the latter now running at $55.8 million per quarter and growing. The board filed routine Form 144 notices on 1 June 2026, a disclosure that reads like a filing trail stack drawer opening to let liquidity into the market without fanfare. The balance sheet is healthy, but the income statement still leans on licence cheques rather than pill bottles.

The company’s guidance range includes the impact of the 3% US wholesale price increase, which is a neat way to frame revenue without changing the underlying product mix. The cost of goods sold sits between 3.5% and 4.5% of net product revenues, a margin that suggests the real value is in the pricing power and the filing trail rather than the pill itself. The R&D spend is large at $199.9 million, but the filing doesn’t say how many of those dollars turned into revenue-generating assets. The inventory build is small at $3.4 million, a rounding error compared with the cash on hand, but still a reminder that oncology is a just-in-time business.

For a closer look at the stock’s chart context, see TradingView’s EXEL chart-just don’t expect the candlesticks to tell you why collaboration revenue rose while product sales didn’t. The market mechanism is there, but the driver is in the filings, not the candles.

What remains unproven is whether Exelixis can convert its R&D spend into product revenues that meaningfully exceed licence fees. The company’s cash flow is strong, but it’s still more licence-driven than pill-driven. The next catalyst would be a product approval or a meaningful uptick in CABOMETYX or COMETRIQ sales that doesn’t rely on a wholesale price hike. Until then, the polished oncology story is still tethered to the ledger by licence cheques and pricing power.